Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,198,990
  • Shares Outstanding, K 97,000
  • Annual Sales, $ 55,850 K
  • Annual Income, $ -212,150 K
  • 60-Month Beta 1.69
  • Price/Sales 38.92
  • Price/Cash Flow N/A
  • Price/Book 3.74
Trade FATE with:

Options Overview Details

View History
  • Implied Volatility 101.13% ( -2.97%)
  • Historical Volatility 74.79%
  • IV Percentile 85%
  • IV Rank 59.35%
  • IV High 126.46% on 06/13/22
  • IV Low 64.15% on 10/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 104
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 3,376
  • Open Int (30-Day) 3,053

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.90
  • Number of Estimates 12
  • High Estimate -0.79
  • Low Estimate -1.06
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -57.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.00 +11.76%
on 09/26/22
29.42 -20.22%
on 09/12/22
-3.25 (-12.16%)
since 09/02/22
3-Month
21.00 +11.76%
on 09/26/22
37.13 -36.79%
on 08/08/22
-1.67 (-6.64%)
since 07/01/22
52-Week
17.10 +37.25%
on 06/13/22
66.56 -64.74%
on 12/23/21
-32.94 (-58.39%)
since 10/04/21

Most Recent Stories

More News
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

XBI : 81.91 (+2.41%)
IBB : 121.81 (+2.16%)
FATE : 23.37 (+3.09%)
FBT : 137.36 (+1.97%)
IOVA : 9.77 (+4.60%)
TWST : 39.18 (+8.59%)
3 Cathie Wood Stocks for the Future

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.

FATE : 23.37 (+3.09%)
VCYT : 18.34 (+7.31%)
ADPT : 8.19 (+12.97%)
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues in the second quarter.

DVAX : 10.98 (+1.57%)
JNJ : 164.66 (+0.89%)
ALKS : 22.76 (-0.83%)
FATE : 23.37 (+3.09%)
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FATE : 23.37 (+3.09%)
RXDX : 60.04 (+0.07%)
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed...

FATE : 23.37 (+3.09%)
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...

FATE : 23.37 (+3.09%)
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

XBI : 81.91 (+2.41%)
IBB : 121.81 (+2.16%)
FATE : 23.37 (+3.09%)
FBT : 137.36 (+1.97%)
IOVA : 9.77 (+4.60%)
TWST : 39.18 (+8.59%)
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate

Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.

BEAM : 50.67 (+5.80%)
ANIK : 24.51 (+1.45%)
FATE : 23.37 (+3.09%)
ACAD : 17.48 (+2.58%)
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

BEAM : 50.67 (+5.80%)
ANIK : 24.51 (+1.45%)
RARE : 42.34 (+0.98%)
FATE : 23.37 (+3.09%)
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

FATE : 23.37 (+3.09%)
LPTX : 0.9111 (+1.23%)
DTIL : 1.4700 (+5.00%)
AMYT : 7.31 (+5.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the...

See More

Key Turning Points

3rd Resistance Point 24.32
2nd Resistance Point 23.73
1st Resistance Point 23.20
Last Price 23.37
1st Support Level 22.08
2nd Support Level 21.49
3rd Support Level 20.96

See More

52-Week High 66.56
Fibonacci 61.8% 47.67
Fibonacci 50% 41.83
Fibonacci 38.2% 35.99
Last Price 23.37
52-Week Low 17.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar